Distinct Nrf2 signaling mechanisms of fumaric acid esters and their role in neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-induced experimental parkinson’s-like disease

Manuj Ahuja, Navneet Ammal Kaidery, Lichuan Yang, Noel Calingasan, Natalya Smirnova, Arsen Gaisin, Irina N. Gaisina, Irina Gazaryan, Dmitry M. Hushpulian, Ismail Kaddour-Djebbar, Wendy B Bollag, John Christopher Morgan, Rajiv R. Ratan, Anatoly A. Starkov, M. Flint Beal, Bobby Thomas

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

A promising approach to neurotherapeutics involves activating the nuclear-factor-E2-related factor 2 (Nrf2)/antioxidant response ele-ment signaling, which regulates expression of antioxidant, anti-inflammatory, and cytoprotective genes. Tecfidera, a putative Nrf2 activator, is an oral formulation of dimethylfumarate (DMF) used to treat multiple sclerosis. We compared the effects of DMF and its bioactive metabolite monomethylfumarate (MMF) on Nrf2 signaling and their ability to block 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced experimental Parkinson’s disease (PD). We show that in vitro DMF and MMF activate the Nrf2 pathway via S-alkylation of the Nrf2 inhibitor Keap1 and by causing nuclear exit of the Nrf2 repressor Bach1. Nrf2 activation by DMF but not MMF was associated with depletion of glutathione, decreased cell viability, and inhibition of mitochondrial oxygen consumption and glycolysis rates in a dose-dependent manner, whereas MMF increased these activities in vitro. However, both DMF and MMF upregulated mitochondrial biogenesis in vitro in an Nrf2-dependent manner. Despite the in vitro differences, both DMF and MMF exerted similar neuroprotective effects and blocked MPTP neurotoxicity in wild-type but not in Nrf2 null mice. Our data suggest that DMF and MMF exhibit neuroprotective effects against MPTP neurotoxicity because of their distinct Nrf2-mediated antioxidant, anti-inflammatory, and mitochondrial functional/biogenetic effects, but MMF does so without depleting glutathione and inhibiting mitochondrial and glycolytic functions. Given that oxidative damage, neuroinflammation, and mitochondrial dysfunction are all implicated in PD pathogenesis, our results provide preclinical evidence for the development of MMF rather than DMF as a novel PD therapeutic.

Original languageEnglish (US)
Pages (from-to)6332-6351
Number of pages20
JournalJournal of Neuroscience
Volume36
Issue number23
DOIs
StatePublished - Jun 8 2016

Fingerprint

NF-E2-Related Factor 2
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Fumarates
Parkinsonian Disorders
Antioxidants
Neuroprotective Agents
Glutathione
Parkinson Disease
Anti-Inflammatory Agents
Neuroprotection
citraconic acid
Dimethyl Fumarate
Alkylation
Organelle Biogenesis
Glycolysis
Oxygen Consumption
Multiple Sclerosis
Cell Survival

Keywords

  • Fumarates
  • Inflammation
  • MPTP
  • Mitochondria
  • Nrf2
  • Oxidative stress

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Distinct Nrf2 signaling mechanisms of fumaric acid esters and their role in neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-induced experimental parkinson’s-like disease. / Ahuja, Manuj; Kaidery, Navneet Ammal; Yang, Lichuan; Calingasan, Noel; Smirnova, Natalya; Gaisin, Arsen; Gaisina, Irina N.; Gazaryan, Irina; Hushpulian, Dmitry M.; Kaddour-Djebbar, Ismail; Bollag, Wendy B; Morgan, John Christopher; Ratan, Rajiv R.; Starkov, Anatoly A.; Beal, M. Flint; Thomas, Bobby.

In: Journal of Neuroscience, Vol. 36, No. 23, 08.06.2016, p. 6332-6351.

Research output: Contribution to journalArticle

Ahuja, M, Kaidery, NA, Yang, L, Calingasan, N, Smirnova, N, Gaisin, A, Gaisina, IN, Gazaryan, I, Hushpulian, DM, Kaddour-Djebbar, I, Bollag, WB, Morgan, JC, Ratan, RR, Starkov, AA, Beal, MF & Thomas, B 2016, 'Distinct Nrf2 signaling mechanisms of fumaric acid esters and their role in neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-induced experimental parkinson’s-like disease', Journal of Neuroscience, vol. 36, no. 23, pp. 6332-6351. https://doi.org/10.1523/JNEUROSCI.0426-16.2016
Ahuja, Manuj ; Kaidery, Navneet Ammal ; Yang, Lichuan ; Calingasan, Noel ; Smirnova, Natalya ; Gaisin, Arsen ; Gaisina, Irina N. ; Gazaryan, Irina ; Hushpulian, Dmitry M. ; Kaddour-Djebbar, Ismail ; Bollag, Wendy B ; Morgan, John Christopher ; Ratan, Rajiv R. ; Starkov, Anatoly A. ; Beal, M. Flint ; Thomas, Bobby. / Distinct Nrf2 signaling mechanisms of fumaric acid esters and their role in neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-induced experimental parkinson’s-like disease. In: Journal of Neuroscience. 2016 ; Vol. 36, No. 23. pp. 6332-6351.
@article{466e981308dc43a4ade304c9af5c162b,
title = "Distinct Nrf2 signaling mechanisms of fumaric acid esters and their role in neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-induced experimental parkinson’s-like disease",
abstract = "A promising approach to neurotherapeutics involves activating the nuclear-factor-E2-related factor 2 (Nrf2)/antioxidant response ele-ment signaling, which regulates expression of antioxidant, anti-inflammatory, and cytoprotective genes. Tecfidera, a putative Nrf2 activator, is an oral formulation of dimethylfumarate (DMF) used to treat multiple sclerosis. We compared the effects of DMF and its bioactive metabolite monomethylfumarate (MMF) on Nrf2 signaling and their ability to block 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced experimental Parkinson’s disease (PD). We show that in vitro DMF and MMF activate the Nrf2 pathway via S-alkylation of the Nrf2 inhibitor Keap1 and by causing nuclear exit of the Nrf2 repressor Bach1. Nrf2 activation by DMF but not MMF was associated with depletion of glutathione, decreased cell viability, and inhibition of mitochondrial oxygen consumption and glycolysis rates in a dose-dependent manner, whereas MMF increased these activities in vitro. However, both DMF and MMF upregulated mitochondrial biogenesis in vitro in an Nrf2-dependent manner. Despite the in vitro differences, both DMF and MMF exerted similar neuroprotective effects and blocked MPTP neurotoxicity in wild-type but not in Nrf2 null mice. Our data suggest that DMF and MMF exhibit neuroprotective effects against MPTP neurotoxicity because of their distinct Nrf2-mediated antioxidant, anti-inflammatory, and mitochondrial functional/biogenetic effects, but MMF does so without depleting glutathione and inhibiting mitochondrial and glycolytic functions. Given that oxidative damage, neuroinflammation, and mitochondrial dysfunction are all implicated in PD pathogenesis, our results provide preclinical evidence for the development of MMF rather than DMF as a novel PD therapeutic.",
keywords = "Fumarates, Inflammation, MPTP, Mitochondria, Nrf2, Oxidative stress",
author = "Manuj Ahuja and Kaidery, {Navneet Ammal} and Lichuan Yang and Noel Calingasan and Natalya Smirnova and Arsen Gaisin and Gaisina, {Irina N.} and Irina Gazaryan and Hushpulian, {Dmitry M.} and Ismail Kaddour-Djebbar and Bollag, {Wendy B} and Morgan, {John Christopher} and Ratan, {Rajiv R.} and Starkov, {Anatoly A.} and Beal, {M. Flint} and Bobby Thomas",
year = "2016",
month = "6",
day = "8",
doi = "10.1523/JNEUROSCI.0426-16.2016",
language = "English (US)",
volume = "36",
pages = "6332--6351",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "23",

}

TY - JOUR

T1 - Distinct Nrf2 signaling mechanisms of fumaric acid esters and their role in neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-induced experimental parkinson’s-like disease

AU - Ahuja, Manuj

AU - Kaidery, Navneet Ammal

AU - Yang, Lichuan

AU - Calingasan, Noel

AU - Smirnova, Natalya

AU - Gaisin, Arsen

AU - Gaisina, Irina N.

AU - Gazaryan, Irina

AU - Hushpulian, Dmitry M.

AU - Kaddour-Djebbar, Ismail

AU - Bollag, Wendy B

AU - Morgan, John Christopher

AU - Ratan, Rajiv R.

AU - Starkov, Anatoly A.

AU - Beal, M. Flint

AU - Thomas, Bobby

PY - 2016/6/8

Y1 - 2016/6/8

N2 - A promising approach to neurotherapeutics involves activating the nuclear-factor-E2-related factor 2 (Nrf2)/antioxidant response ele-ment signaling, which regulates expression of antioxidant, anti-inflammatory, and cytoprotective genes. Tecfidera, a putative Nrf2 activator, is an oral formulation of dimethylfumarate (DMF) used to treat multiple sclerosis. We compared the effects of DMF and its bioactive metabolite monomethylfumarate (MMF) on Nrf2 signaling and their ability to block 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced experimental Parkinson’s disease (PD). We show that in vitro DMF and MMF activate the Nrf2 pathway via S-alkylation of the Nrf2 inhibitor Keap1 and by causing nuclear exit of the Nrf2 repressor Bach1. Nrf2 activation by DMF but not MMF was associated with depletion of glutathione, decreased cell viability, and inhibition of mitochondrial oxygen consumption and glycolysis rates in a dose-dependent manner, whereas MMF increased these activities in vitro. However, both DMF and MMF upregulated mitochondrial biogenesis in vitro in an Nrf2-dependent manner. Despite the in vitro differences, both DMF and MMF exerted similar neuroprotective effects and blocked MPTP neurotoxicity in wild-type but not in Nrf2 null mice. Our data suggest that DMF and MMF exhibit neuroprotective effects against MPTP neurotoxicity because of their distinct Nrf2-mediated antioxidant, anti-inflammatory, and mitochondrial functional/biogenetic effects, but MMF does so without depleting glutathione and inhibiting mitochondrial and glycolytic functions. Given that oxidative damage, neuroinflammation, and mitochondrial dysfunction are all implicated in PD pathogenesis, our results provide preclinical evidence for the development of MMF rather than DMF as a novel PD therapeutic.

AB - A promising approach to neurotherapeutics involves activating the nuclear-factor-E2-related factor 2 (Nrf2)/antioxidant response ele-ment signaling, which regulates expression of antioxidant, anti-inflammatory, and cytoprotective genes. Tecfidera, a putative Nrf2 activator, is an oral formulation of dimethylfumarate (DMF) used to treat multiple sclerosis. We compared the effects of DMF and its bioactive metabolite monomethylfumarate (MMF) on Nrf2 signaling and their ability to block 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced experimental Parkinson’s disease (PD). We show that in vitro DMF and MMF activate the Nrf2 pathway via S-alkylation of the Nrf2 inhibitor Keap1 and by causing nuclear exit of the Nrf2 repressor Bach1. Nrf2 activation by DMF but not MMF was associated with depletion of glutathione, decreased cell viability, and inhibition of mitochondrial oxygen consumption and glycolysis rates in a dose-dependent manner, whereas MMF increased these activities in vitro. However, both DMF and MMF upregulated mitochondrial biogenesis in vitro in an Nrf2-dependent manner. Despite the in vitro differences, both DMF and MMF exerted similar neuroprotective effects and blocked MPTP neurotoxicity in wild-type but not in Nrf2 null mice. Our data suggest that DMF and MMF exhibit neuroprotective effects against MPTP neurotoxicity because of their distinct Nrf2-mediated antioxidant, anti-inflammatory, and mitochondrial functional/biogenetic effects, but MMF does so without depleting glutathione and inhibiting mitochondrial and glycolytic functions. Given that oxidative damage, neuroinflammation, and mitochondrial dysfunction are all implicated in PD pathogenesis, our results provide preclinical evidence for the development of MMF rather than DMF as a novel PD therapeutic.

KW - Fumarates

KW - Inflammation

KW - MPTP

KW - Mitochondria

KW - Nrf2

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=84973345878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973345878&partnerID=8YFLogxK

U2 - 10.1523/JNEUROSCI.0426-16.2016

DO - 10.1523/JNEUROSCI.0426-16.2016

M3 - Article

C2 - 27277809

AN - SCOPUS:84973345878

VL - 36

SP - 6332

EP - 6351

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 23

ER -